Avalo Therapeutics (NASDAQ:AVTX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Avalo Therapeutics (NASDAQ:AVTX) from a strong sell rating to a hold rating in a research note published on Sunday morning.

A number of other analysts have also commented on AVTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. BTIG Research restated a “buy” rating and issued a $40.00 target price on shares of Avalo Therapeutics in a report on Tuesday, March 24th. HC Wainwright lifted their price target on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. Guggenheim initiated coverage on shares of Avalo Therapeutics in a research report on Monday, February 2nd. They issued a “buy” rating and a $50.00 price objective for the company. Finally, Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.25.

Avalo Therapeutics Stock Performance

AVTX stock opened at $13.89 on Friday. The stock’s 50 day moving average price is $15.47 and its 200 day moving average price is $15.84. The firm has a market cap of $316.55 million, a P/E ratio of -2.42 and a beta of 0.84. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($1.54) by $1.17. The company had revenue of $0.06 million for the quarter, compared to analysts’ expectations of ($0.21) million. On average, research analysts predict that Avalo Therapeutics will post -19.07 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Mittie Doyle sold 25,492 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $16.15, for a total transaction of $411,695.80. Following the completion of the transaction, the insider owned 3,622 shares of the company’s stock, valued at $58,495.30. This represents a 87.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.25% of the stock is owned by company insiders.

Hedge Funds Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AVTX. Orbimed Advisors LLC raised its stake in Avalo Therapeutics by 39.5% during the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock worth $17,150,000 after purchasing an additional 382,300 shares during the period. Nantahala Capital Management LLC grew its stake in shares of Avalo Therapeutics by 24.1% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock valued at $15,697,000 after buying an additional 240,000 shares during the period. Affinity Asset Advisors LLC increased its holdings in shares of Avalo Therapeutics by 4.5% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,051,054 shares of the company’s stock worth $19,087,000 after buying an additional 44,837 shares during the last quarter. Caligan Partners LP raised its position in shares of Avalo Therapeutics by 5.8% in the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock worth $16,009,000 after buying an additional 48,200 shares during the period. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Avalo Therapeutics in the 3rd quarter worth $10,390,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.